Because of the efficacy of biologics in treating complex diseases with fewer side effects than traditional small molecule drugs, biopharmaceutical companies are looking to increase the percentage of biologic-based drugs in their portfolios and pipelines. This market research report focuses on this growth and indicates what percentage of those projects will be outsourced to contract manufacturers over the next five years.
This report will help you learn outsourcing motivations, project volume, and average project cost comparisons between mammalian and microbial-expression systems. It will also show at what point in the drug development cycle drug developers are likely to engage CMOs for bioprocessing services and whether that differs depending on the expression system. It also offers a prediction of the capabilities sponsors will need for biological products in development five years from now.
Drug developers can use this market research report to understand which capabilities and services their peers are outsourcing to contract manufacturers , and to identify service areas where there might be too much competition to outsource/lack of available capacity.
CMOs can use the report to prepare for changes in demand by gaining insight into the current and future outsourced bioprocessing services marketplace, and to determine how well their company’s offering matches the attributes most desired by sponsors.
Download the preview file for more information.